Genmab: Eppkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff (GMAB)

Genmab A/S is a solid buy with undervalued stock, robust royalties, and blockbuster ADC potential. Click for my look at GMAB and why I am bullish.